Indivior (NASDAQ:INDV) Shares Gap Down to $11.09

Indivior PLC (NASDAQ:INDV)’s share price gapped down prior to trading on Friday . The stock had previously closed at $11.09, but opened at $10.66. Indivior shares last traded at $10.83, with a volume of 410,034 shares traded.

Analyst Ratings Changes

A number of brokerages recently commented on INDV. Craig Hallum lowered their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Piper Sandler initiated coverage on shares of Indivior in a research report on Tuesday, July 23rd. They issued an “overweight” rating and a $22.00 price target on the stock.

Indivior Stock Performance

The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. The stock has a fifty day moving average price of $12.57 and a two-hundred day moving average price of $16.75. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 1,070.00 and a beta of 0.69.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The firm had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. As a group, analysts forecast that Indivior PLC will post 1.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of INDV. Norges Bank purchased a new stake in shares of Indivior in the fourth quarter valued at $36,011,000. UBS Group AG grew its holdings in Indivior by 71.9% in the 4th quarter. UBS Group AG now owns 826,130 shares of the company’s stock valued at $12,615,000 after buying an additional 345,556 shares during the period. Renaissance Group LLC increased its stake in shares of Indivior by 6.1% during the 4th quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock valued at $1,573,000 after acquiring an additional 5,896 shares during the last quarter. Campbell & CO Investment Adviser LLC lifted its holdings in shares of Indivior by 2.8% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after acquiring an additional 1,037 shares during the period. Finally, Premier Fund Managers Ltd boosted its position in shares of Indivior by 17.8% in the fourth quarter. Premier Fund Managers Ltd now owns 850,980 shares of the company’s stock worth $12,901,000 after acquiring an additional 128,611 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.